VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Measuring residual disease in granulocytes to predict relapse after therapy cessation in CML

Ilaria Pagani, PhD, University of Adelaide, Adelaide, Australia, comments on the monitoring of residual disease in patients with chronic myeloid leukemia (CML) to detect relapse after therapy cessation using a novel sensitive method. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter